Stock listing

BMV:TEM Tempus AI, Inc. Acciones

Mexican listing (BMV) of Tempus AI, Inc. · home listing NASDAQ:TEM

Follow Tempus AI, Inc. into a list and get an email when it puts out news.

Share price · BMV:TEM

$1,340.12 MXN +106.90 (+8.7%)

Close on Oct 27, 2026

Day range
$1,336.00 – $1,355.00 MXNOct 27, 2026
Volume
655 sharesOct 27, 2026
Market cap
$243.3B MXNAt the close on Oct 27, 2026 · price × 181.6M shares outstanding
Tempus AI, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:TEM · Home$72.22 USD-5.62 (-7.2%)10,418,259$73.49$76.65$70.86$77.84Close on Oct 30, 2026
BMV:TEM$1,340.12 MXN+106.90 (+8.7%)655$1,336.00$1,355.00$1,336.00$1,233.22Close on Oct 27, 2026
Frankfurt:F3M€64.99 EUR+5.60 (+9.4%)—€65.38€65.40€64.99€59.39Close on Oct 30, 2026
Ticker
BMV:TEM
Asset type
Stock
Exchange
BMV
Currency
MXN

What changed lately

Calls

Upcoming

  • Tempus AI (NASDAQ:TEM) Q3 2026 Earnings Call

    Mon, Nov 02, 2026 · 8:45 AM ET

    Register

Replays

  • Tempus AI (NASDAQ:TEM) Q2 2026 Earnings Call

    Thu, Jul 30, 2026 · 4:30 PM ET

    Watch Transcript

  • Tempus AI (NASDAQ:TEM) Q1 2026 Earnings Call

    Tue, May 05, 2026 · 4:30 PM ET

    Watch Transcript

  • Tempus AI (NASDAQ:TEM) Q4 2025 Earnings Call

    Tue, Feb 24, 2026 · 4:30 PM ET

    Watch Transcript

Latest news

Tempus Receives IVDR Certification for xR RNA Sequencing for Solid Tumor Profiling

Oct 26, 2026

Tempus Expands Strategic Collaboration with Bristol Myers Squibb

Oct 23, 2026

Tempus Presents Data Demonstrating AI-Enabled Pre-Screening Can Help Identify Patients for Biomarker Testing in NSCLC

Oct 19, 2026

Tempus to Report Third Quarter 2026 Financial Results on November 2

Oct 15, 2026

Ambry Genetics Announces GenomeNext™, a Whole Genome Sequencing Test Solution to Improve Diagnosis for Rare Diseases

Oct 13, 2026

Tempus Announces Multi-Year Collaboration with Moderna and Merck

Oct 7, 2026

Tempus Announces 13 Abstracts Accepted for Presentation at the European Society for Medical Oncology Congress 2026

Oct 1, 2026

Tempus Receives FDA Clearance for its ECG-MR AI Product Designed to Identify Undiagnosed Mitral Regurgitation

Sep 28, 2026

Tempus and Recursion Extend Existing Data License Agreement and Enter New License Agreement for Recursion’s RNA Foundation Model

Sep 21, 2026

Tempus Launches Effort to Build the Largest Multimodal Whole-Genome Dataset to Advance AI-Driven Healthcare Innovation

Sep 11, 2026

All Tempus AI, Inc. news

Financings

Read by 6ix AI from the company's releases

Decks

Tempus AI, Inc. on 6ix

News releases
70 in the last 12 months · 159 in all · newest Oct 26, 2026 · oldest 2024
Calls
9 calls with a replay · 9 with a transcript · latest Jul 30, 2026
Decks
16 decks · latest Jul 30, 2026

Where Tempus AI, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:TEM · Home listingNASDAQUnited StatesUSD
gettex:F3MgettexGermanyEUR
Tradegate:F3MTradegateGermanyEUR
BCBA:TEMBCBAArgentinaARS
BOATS:TEMBOATSUnited StatesUSD
BMV:TEM · This pageBMVMexicoMXN
Lang & Schwarz:A40EDPLang & SchwarzGermanyEUR
LS Exchange:A40EDPLS ExchangeGermanyEUR
Milan:1TEMMilanItalyEUR
Frankfurt:F3MFrankfurtGermanyEUR
BX Swiss:TEMUSDBX SwissSwitzerlandUSD
BCBA:TEMCBCBAArgentinaUSD
BCBA:TEMDBCBAArgentinaUSD
BIVA:TEMBIVAMexicoMXN
Munich:F3MMunichGermanyEUR
BX Swiss:TEMBX SwissSwitzerlandCHF
Dusseldorf:F3MDusseldorfGermanyEUR
Hamburg:F3MHamburgGermanyEUR
Stuttgart:F3MStuttgartGermanyEUR
BCBA:TEM.CIBCBAArgentinaARS
Hanover:F3MHanoverGermanyEUR
Xetra:F3MXetraGermanyEUR

Log in to ask 6ix AI your own questions about Tempus AI, Inc.